Modality
Gene Editing
MOA
BETi
Target
SGLT2
Pathway
RNA Splicing
T2DAS
Development Pipeline
Preclinical
Dec 2020
→ Jan 2025
PreclinicalCurrent
NCT06168820
388 pts·T2D
2021-04→TBD·Active
NCT04520028
1,805 pts·AS
2020-12→2025-01·Not yet recruiting
2,193 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-051.2y agoInterim· AS
2026-09-276mo awayBTD· AS
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2025-01-05 · 1.2y ago
AS
BTD
2026-09-27 · 6mo away
AS
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06168820 | Preclinical | T2D | Active | 388 | FEV1 |
| NCT04520028 | Preclinical | AS | Not yet recr... | 1805 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα |